Sermorelin Missed Dose: Why the Dispensed Instructions Control

The Missing Instruction Cannot Be Invented From Physiology

FDA states of compounded medicines:

“Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”

The issuer is the U.S. Food and Drug Administration. This 24-word passage explains why an old approved-product record cannot automatically validate the strength, stability, administration schedule, or missed-dose rule for a present compounded vial. It does not say every compounded product is defective or imply FDA endorsement of any alternative (FDA, “Are compounded drugs approved by FDA?”).

Sermorelin stimulates growth-hormone release, but mechanism does not answer whether a late dose should be taken, skipped, shifted, or withheld. That decision also depends on the prescribed frequency, the dispensed concentration, the actual administration time, other medicines, and whether a dose may already have been taken.

The Instruction-Provenance Ladder

The practical order is therefore simple: check the actual label first. If it is silent, ask the dispensing pharmacist or prescriber. Do not reconstruct a dose from a generic web page.

Figure 1

A missed or doubled sermorelin dose: whose instruction applies

Text version of this diagram

1. No current FDA label to fall back on: FDA withdrew approval of both Geref sermorelin products effective June 18, 2009. Compounded sermorelin is not FDA-approved, and FDA does not verify it before it is marketed.
2. Do the dispensing label or written prescription give a missed-dose instruction?
   • Yes: Follow it for this product.
   • No, or unclear: Contact the dispensing pharmacist or prescriber before taking more.
3. Could a dose have been taken twice, or are there unexpected symptoms?
   • Yes: Record product, concentration, amount, time and symptoms, then get case-specific advice before any further dose.
   • No: Follow the label instruction or the answer you were given, and ask for any spoken answer in writing.
4. What the historical trial shows: The Geref pediatric trial gave sermorelin once daily at bedtime for up to 1 year. Its abstract reports no missed-dose, late-dose or catch-up comparison.

What the Historical Record Actually Shows

FDA records distinguish two former products. Geref Diagnostic was approved as a single-dose test of pituitary growth-hormone reserve, while Geref Pediatric was approved for treatment of growth failure in children with growth-hormone deficiency. FDA's current Orange Book lists the relevant Geref applications as discontinued and marks them as not discontinued or withdrawn for safety or effectiveness reasons. A later FDA review states that the same GHRH(1–29) formulation had been used for the diagnostic and pediatric products, but with different purposes and dosing contexts (FDA EGRIFTA medical review, section 2.4).

The multicenter pediatric study used once-daily bedtime dosing for up to one year in previously untreated prepubertal children with GH deficiency. That supports the existence of a studied historical schedule; its abstract does not report a missed-dose comparison, a late-dose arm, or a catch-up rule (PMID 8772599).

The distinction matters. “A dose was historically given at bedtime” is not the same claim as “taking a late dose is unsafe,” “one missed dose is clinically trivial,” or “resume the following night.”

A Missed-Dose Decision Record

Before requesting advice, capture the fields that actually change the answer:

1. Exact pharmacy and product name.
2. Concentration on the vial and amount on the dispensing label.
3. Prescribed frequency and usual administration time.
4. When the last confirmed dose was taken.
5. Whether the dose was definitely missed or may have been duplicated.
6. Current symptoms and relevant medicines or medical conditions.
7. Storage history if the product was left unrefrigerated or otherwise mishandled.

This is more useful than quoting a short plasma half-life. A half-life does not identify the compounded product, prove what amount entered the body, or establish an evidence-based replacement window.

Missed-Dose Rules the Evidence Does Not Support

Missed-dose advice for sermorelin sometimes includes a universal “skip and resume at bedtime” rule, a typical dose and empty-stomach window, claims that a missed night is trivial, predictions of when IGF-1 will fall, and travel and refrigeration cutoffs. It may also invoke receptor desensitization and somatostatin feedback to warn against a double dose.

No cited study directly tested those missed-dose outcomes in the products now dispensed as compounded sermorelin. Some statements may resemble reasonable clinical habits, but a habit is not a product-specific evidence base.

The food and supplement evidence map applies the same distinction to meal and supplement claims. The nutrition audit separates human glucose-challenge physiology from a fasting protocol, and the storage and stability review addresses a different product-quality question.

The Responsible Current Answer

If the written instructions clearly address a missed dose, follow them. If they do not, or if a duplicate dose may have occurred, contact the dispensing pharmacist or prescriber before taking more. For a possible overdose or unexpected symptoms in the United States, Poison Control can provide case-specific triage at 1-800-222-1222; call 911 for collapse, seizure, trouble breathing, or inability to awaken.

This page cannot determine whether a dose was delivered, clear a possible dosing error, or replace the product-specific instructions.

Medical review of this revision is pending. FDA, sponsors, investigators, institutions, pharmacists, clinicians, and authors do not endorse sermorelin, HealthRX.com, or this page.